Growing community of inventors

Roxbury, CT, United States of America

Kristine A Erickson

Average Co-Inventor Count = 8.47

ph-index = 1

The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.

Forward Citations = 2

Kristine A EricksonKaren W Chu (2 patents)Kristine A EricksonRobert L Vitti (2 patents)Kristine A EricksonDaniel B Dix (1 patent)Kristine A EricksonKenneth S Graham (1 patent)Kristine A EricksonStanley J Wiegand (1 patent)Kristine A EricksonJingtai Cao (1 patent)Kristine A EricksonIvan Borisovich Lobov (1 patent)Kristine A EricksonSaurabh Wadhwa (1 patent)Kristine A EricksonRonald Buggage (1 patent)Kristine A EricksonValérie Corp Dit Genti (1 patent)Kristine A EricksonDominique Mery-Mignard (1 patent)Kristine A EricksonRafael Varona (1 patent)Kristine A EricksonPreethi Aavali Sridhara Sundaram (1 patent)Kristine A EricksonKristine A Erickson (2 patents)Karen W ChuKaren W Chu (5 patents)Robert L VittiRobert L Vitti (4 patents)Daniel B DixDaniel B Dix (51 patents)Kenneth S GrahamKenneth S Graham (25 patents)Stanley J WiegandStanley J Wiegand (23 patents)Jingtai CaoJingtai Cao (13 patents)Ivan Borisovich LobovIvan Borisovich Lobov (12 patents)Saurabh WadhwaSaurabh Wadhwa (3 patents)Ronald BuggageRonald Buggage (1 patent)Valérie Corp Dit GentiValérie Corp Dit Genti (1 patent)Dominique Mery-MignardDominique Mery-Mignard (1 patent)Rafael VaronaRafael Varona (1 patent)Preethi Aavali Sridhara SundaramPreethi Aavali Sridhara Sundaram (1 patent)
..
Inventor’s number of patents
..
Strength of working relationships

Company Filing History:

1. Regeneron Pharmaceuticals, Inc. (2 from 1,342 patents)

2. Sanofi Biotechnology (1 from 37 patents)


2 patents:

1. 11071780 - Methods and formulations for treating vascular eye diseases using aflibercept and nesvacumab

2. 10968278 - Compositions comprising IL6R antibodies for the treatment of uveitis and macular edema and methods of using same

Please report any incorrect information to support@idiyas.com
idiyas.com
as of
12/4/2025
Loading…